MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
2.975
-0.155
-4.95%
Opening 12:47 02/12 EST
OPEN
3.190
PREV CLOSE
3.130
HIGH
3.190
LOW
2.960
VOLUME
1.86M
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.891
MARKET CAP
890.52M
P/E (TTM)
-5.1613
1D
5D
1M
3M
1Y
5Y
1D
3 Promising Penny Stocks With At Least $600M Market Cap
Simply Wall St · 7h ago
AbCellera Biologics to Present at Major Investor Conferences
Reuters · 21h ago
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
Barchart · 1d ago
Weekly Report: what happened at ABCL last week (0202-0206)?
Weekly Report · 3d ago
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions?
Simply Wall St · 6d ago
OpenAI considers backing AI-led drug discovery firms: report
Seeking Alpha · 02/03 20:06
Weekly Report: what happened at ABCL last week (0126-0130)?
Weekly Report · 02/02 09:09
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
Simply Wall St · 01/30 08:38
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.